Natural and synthetic bioactive inhibitors of glycogen synthase kinase

Eur J Med Chem. 2017 Jan 5:125:464-477. doi: 10.1016/j.ejmech.2016.09.058. Epub 2016 Sep 20.

Abstract

Glycogen synthase kinase-3 is a multi-functional serine-threonine kinase and is involved in diverse physiological processes, including metabolism, cell cycle, and gene expression by regulating a wide variety of known substrates like glycogen synthase, tau-protein and β-catenin. Aberrant GSK-3 has been involved in diabetes, inflammation, cancer, Alzheimer's and bipolar disorder. In this review, we present an overview of the involvement of GSK-3 in various signalling pathways, resulting in a number of adverse pathologies due to its dysregulation. In addition, a detailed description of the small molecule inhibitors of GSK-3 with different mode of action discovered or specifically developed for GSK-3 has been presented. Furthermore, some clues for the future optimization of these promising molecules to develop specific drugs inhibiting GSK-3, for the treatment of associated disease conditions have also been discussed.

Keywords: ATP; Alzheimer's disease; Diabetes; Glycogen synthase kinase; Kinases; Phosphorylation.

Publication types

  • Review

MeSH terms

  • Alzheimer Disease / drug therapy
  • Alzheimer Disease / metabolism
  • Animals
  • Bipolar Disorder / drug therapy
  • Bipolar Disorder / metabolism
  • Clinical Trials as Topic
  • Diabetes Mellitus / drug therapy
  • Diabetes Mellitus / metabolism
  • Drug Discovery*
  • Glycogen Synthase Kinase 3 / antagonists & inhibitors*
  • Glycogen Synthase Kinase 3 / metabolism
  • Humans
  • Models, Molecular
  • Neoplasms / drug therapy
  • Neoplasms / metabolism
  • Patents as Topic
  • Phosphorylation / drug effects
  • Protein Kinase Inhibitors / chemistry*
  • Protein Kinase Inhibitors / pharmacology*
  • Signal Transduction / drug effects*

Substances

  • Protein Kinase Inhibitors
  • Glycogen Synthase Kinase 3